Recognises β-Catenin a key protein in the Wnt signalling pathway, involved in cancer progression
Anti-β-Catenin antibody (crb2005237) (1μg/ml)
Western blot analysis of whole cell extract human embryonic kidney cells HEK293 cells (30µg) and human prostate cancer CWR cells (30µg) .
Lane 1: HEK293 (30ug)
Lane 2: CWR (30ug)
|Antigen Peptide||KLH conjugated synthetic peptide crb1200480e|
|Protein ID||UniProtKB - P35222|
|Aliases||Beta-Catenin, Catenin beta-1,CTNNB|
|Cross-Reactivity||Human, rat, mouse, chicken, rhesus macaque|
|Target Protein Species||Human, rat, mouse, chicken, rhesus macaque|
|Validation||1:1000 (ELISA), 1ug/ml (WB)|
|Storage Stabilisers||This material is supplied in PBS containing 0.01% sodium azide and 1% trehalose. The product should be stored at +4°C for short term storage and -20°C for long term storage. Avoid repeated freeze/ thaw cycles.|
|Disease Area||Cancer, DNA Damage, apoptosis, transcription, cell cycle, signal transduction|
|Storage||This material is supplied in PBS containing 0.01% sodium azide and 1% trehalose. The product should be stored at +4°C for short term storage and -20°C for long term storage. Avoid repeated freeze/ thaw cycles.|
Shang et al., (2017). The regulation of β-catenin activity and function in cancer: therapeutic opportunities. Oncotarget. 8(20): 33972–33989. PMID: 28430641
β-Catenin is a multifunctional protein that acts both as a transcriptional co-regulator and an adaptor protein for intracellular adhesion and is a vital component of the Wnt signalling pathway, an evolutionarily conserved pathway crucially involved in embryonic development and tissue homeostasis.
Wnt signalling pathway is the main regulator of β-catenin, when the pathway is not active, β-catenin is kept at a low level by the ubiquitin proteasome system (UPS). Following nuclear translocation via activation of the Wnt signalling pathway, β-catenin is thought to form a transcriptional complex with DNA binding proteins such as TCF/LEF, p300/CBP to help fulfil its role as a transcriptional activator.
Aberrant activation of Wnt signalling results in the accumulation of β-catenin in the nucleus and promotes the transcription of many oncogenes such as c-Myc and CyclinD-1. Indeed, once in the nucleus, β-catenin binds to several nuclear proteins involved in tumour development or progression such as p300/CBP, TATA-box binding protein (TBP), Pontin52, Reptin52, Brg-1, MUC1-C, SOX10, p68/p72, FOXM1, yes-associated protein 1 (YAP1) and FBW1. Over-expression of β-Catenin has been linked to various diseases including colon cancer, hepatocellular carcinoma, pancreatic cancer, lung cancer, skin cancer breast cancer and ovarian cancer.